EP Patent

EP3384901A1 — Pharmaceutical composition comprising lenvatinib mesylate

Assigned to Synthon BV · Expires 2018-10-10 · 8y expired

What this patent protects

The present invention relates to a pharmaceutical composition comprising a therapeutically effective dose of Lenvatinib mesylate having sodium wherein the weight ratio of Lenvatinib mesylate to sodium carbonates ranges from 1: 1.5 to 1:5.

USPTO Abstract

The present invention relates to a pharmaceutical composition comprising a therapeutically effective dose of Lenvatinib mesylate having sodium wherein the weight ratio of Lenvatinib mesylate to sodium carbonates ranges from 1: 1.5 to 1:5.

Drugs covered by this patent

Patent Metadata

Patent number
EP3384901A1
Jurisdiction
EP
Classification
—
Expires
2018-10-10
Drug substance claim
No
Drug product claim
No
Assignee
Synthon BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.